- Full Year 2023 Medacta Group SA Earnings Call TranscriptMar 13, 2024€78.81Earnings
- Full Year 2023 Medacta Group SA Corporate Sales Call TranscriptFeb 02, 2024
- Half Year 2023 Medacta Group SA Earnings Call TranscriptSep 22, 2023€78.81Earnings
- Half Year 2023 Medacta Group SA Corporate Sales Call TranscriptJul 28, 2023
- Full Year 2022 Medacta Group SA Earnings Call TranscriptMar 17, 2023€78.81Earnings
- Q4 2022 Medacta Group SA Unaudited Top-Line Figures Call TranscriptFeb 03, 2023
- Half Year 2022 Medacta Group SA Earnings Call TranscriptSep 09, 2022€78.81Earnings
- Half Year 2022 Medacta Group SA Earnings Call TranscriptJul 29, 2022€78.81Earnings
- Full Year 2021 Medacta Group SA Earnings Call TranscriptMar 11, 2022€78.81Earnings
- Q4 2021 Medacta Group SA Corporate Sales Call TranscriptJan 20, 2022
- Half Year 2021 Medacta Group SA Earnings Call TranscriptSep 10, 2021€78.81Earnings
- Half Year 2021 Medacta Group SA Corporate Sales Call TranscriptJul 20, 2021
- Full Year 2020 Medacta Group SA Earnings Call TranscriptMar 31, 2021€78.81Earnings
- Full Year 2020 Medacta Group SA Corporate Sales Call TranscriptJan 21, 2021
- Half Year 2020 Medacta Group SA Earnings Call TranscriptSep 07, 2020€78.81Earnings
- Half Year 2020 Medacta Group SA Earnings Call TranscriptJul 22, 2020€78.81Earnings
- Full Year 2019 Medacta Group SA Earnings Call TranscriptApr 06, 2020Earnings
Full Year 2023 Medacta Group SA Corporate Sales Call Transcript
Good afternoon. This is the Chorus Conference operator. Welcome and thank you for joining the Medacta 2023 full-year preliminary unaudited topline figures conference call. (Operator Instructions) At this time, I would like to turn the conference over to Mr. Francesco Siccardi, CEO of Medacta. Please go ahead, sir.
Thank you very much and good afternoon. I'm pleased to present today with Corrado Farsetta, our CFO, the full-year 2023 preliminary unaudited topline figures. In terms of highlights and areas of interest for last year, we are very happy and proud to report a very good performance in terms of topline growth, close to 20% constant currency growth or 16.8% reported, which allowed Medacta for the first time to pass the EUR500-million mark, EUR522.5 million in constant currency or EUR511 million reported.
This performance on top of our ability to gain market share thanks to our different products and solutions was supported as well by some
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)